What's breaking now, across thousands of outlets.
Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
People with Long COVID are at a higher risk for cardiovascular, renal, and pulmonary (CRP) outcomes, according to a large observational study published in Journal of the American Heart Association.
A major trial hints that better blood pressure control may offer an unexpected benefit for brain health.
Patients in addiction treatment are increasingly receiving prescriptions for the nerve pain drug gabapentin, despite a lack of evidence for its effectiveness.
The U.S.’s summer 2026 COVID-19 wave is in full swing. All disease tracking metrics report increased spread across the country, and the school year’s start and upcoming holiday weekend will cause…
[Premium Times] Mr Bulus said the deaths were recorded within three days of the outbreak, warning that the number of cases could increase if urgent measures were not taken to contain the disease
